JP2004534074A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534074A5
JP2004534074A5 JP2003504977A JP2003504977A JP2004534074A5 JP 2004534074 A5 JP2004534074 A5 JP 2004534074A5 JP 2003504977 A JP2003504977 A JP 2003504977A JP 2003504977 A JP2003504977 A JP 2003504977A JP 2004534074 A5 JP2004534074 A5 JP 2004534074A5
Authority
JP
Japan
Prior art keywords
spironolactone
nanoparticulate
nanosuspension
stabilizer
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003504977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534074A (ja
JP4536373B2 (ja
Filing date
Publication date
Priority claimed from GBGB0114532.5A external-priority patent/GB0114532D0/en
Application filed filed Critical
Publication of JP2004534074A publication Critical patent/JP2004534074A/ja
Publication of JP2004534074A5 publication Critical patent/JP2004534074A5/ja
Application granted granted Critical
Publication of JP4536373B2 publication Critical patent/JP4536373B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003504977A 2001-06-14 2002-06-14 新規組成物 Expired - Fee Related JP4536373B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114532.5A GB0114532D0 (en) 2001-06-14 2001-06-14 Novel compositions
PCT/IB2002/003136 WO2002102391A2 (en) 2001-06-14 2002-06-14 Composition comprising nanoparticulate spironolactone

Publications (3)

Publication Number Publication Date
JP2004534074A JP2004534074A (ja) 2004-11-11
JP2004534074A5 true JP2004534074A5 (enExample) 2006-01-05
JP4536373B2 JP4536373B2 (ja) 2010-09-01

Family

ID=9916594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003504977A Expired - Fee Related JP4536373B2 (ja) 2001-06-14 2002-06-14 新規組成物

Country Status (6)

Country Link
US (2) US20040151776A1 (enExample)
EP (1) EP1429781A2 (enExample)
JP (1) JP4536373B2 (enExample)
AU (1) AU2002347094A1 (enExample)
GB (1) GB0114532D0 (enExample)
WO (1) WO2002102391A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US7897691B2 (en) 2008-05-09 2011-03-01 Gm Global Technology Operations, Inc. Proton exchange membranes for fuel cell applications
JP5185039B2 (ja) * 2008-09-24 2013-04-17 富士フイルム株式会社 光学フィルム、その製造方法、並びにそれを用いた偏光板及び液晶表示装置
MA43132A (fr) * 2015-10-30 2018-09-05 Cmp Dev Llc Compositions aqueuses de spironolactone
US10493083B2 (en) 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011316A (en) * 1975-02-24 1977-03-08 Research Institute For Medicine And Chemistry Inc. Cyclohexa-2,5-diene-1-thiones
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
US4837211A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DK1175220T3 (da) * 1999-12-08 2005-08-29 Pharmacia Corp Nanopartikulære eplerenonkompositioner
US20020036154A1 (en) * 2000-08-10 2002-03-28 Ramaswamy Murari Solid pharmaceutical dosage formulation of hydrophobic drugs

Similar Documents

Publication Publication Date Title
Kumar et al. Advanced metal and carbon nanostructures for medical, drug delivery and bio-imaging applications
Lu et al. Graphene-based nanomaterials in biosystems
Osminkina et al. Porous silicon nanoparticles as scavengers of hazardous viruses
Cai et al. Hyaluronan-inorganic nanohybrid materials for biomedical applications
Mbhele et al. Fabrication and characterization of silver− polyvinyl alcohol nanocomposites
Parameswaranpillai et al. Nanocomposite materials: synthesis, properties and applications
WO2004020453A3 (en) Functionalized nanoparticles
JP2004534074A5 (enExample)
Gao et al. Decorating CdTe QD-embedded mesoporous silica nanospheres with Ag NPs to prevent bacteria invasion for enhanced anticounterfeit applications
WO2008027502A3 (en) Carbon nanotube nanocomposites, methods of making carbon nanotube nanocomposites, and devices comprising the nanocomposites
JP2008509068A5 (enExample)
Grumezescu Surface chemistry of nanobiomaterials: applications of nanobiomaterials
JP2006517944A5 (enExample)
JP2009538268A5 (enExample)
WO2009023304A3 (en) High density nanotube devices
WO2006128181A3 (en) Nanoparticle assemblies with molecular spring
de Oliveira et al. Chitosan-based improved stability of gold nanoparticles for the study of adsorption of dyes using SERS
Singh et al. Hybrid silver nanoparticles: Modes of synthesis and various biomedical applications
JP2011111444A5 (enExample)
EP1952919A3 (en) Magnetic nanoparticles and aqueous colloid composition containing the same
López et al. Release of copper complexes from a nanostructured sol–gel titania for cancer treatment
Matharu et al. Exploiting the antiviral potential of intermetallic nanoparticles
JP2008280345A5 (enExample)
WO2002102391A3 (en) Composition comprising nanoparticulate spironolactone
JP2007077035A5 (enExample)